Inve India ▾

Caplin Point Laboratories share price & results

Caplin Point Laboratories Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Chennai pharma maker of generics, branded generics & injectables sold across Latin America, Africa and the US.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue610 ₹ crore+19.6% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin35.0 %0.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit179 ₹ crore+18.5% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity22.15 %−1.8 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin12.57 %+0.2 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)15.04 %−1.4 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

1 of 3 judged targets kept · 10 open · verdicts reflect calls analysed to Q1 FY27.

Caplin Point Laboratories Limited management guidance track record on Inve: 13 targets tracked across analysed earnings calls (1 achieved, 2 missed, 10 open).

TargetOriginal wordingSaidLatest callVerdict
Total ANDA TallyTouching around 45-46 ANDAs in the coming few weeks.
Call transcript, Q2 FY26 · 6 Nov 2025		Q2 FY26Q1 FY27:No new update. Promise was achieved in the previous quarter.
Call transcript, Q1 FY27 · 12 Aug 2026		Achieved
Caplin Steriles $100M Run Rate$100M run rate, to be achieved in 'next year or 18 months after next year'.
Call transcript, Q4 FY25 · 15 May 2025		Q4 FY25Q1 FY27:No specific update on the $100M run rate target, despite extensive discussion on CSL's growth and capacity expansion.
Call transcript, Q1 FY27 · 12 Aug 2026		Ghosted
API Facility CompletionOne API facility to be completed in another 2-3 months.
Call transcript, Q4 FY25 · 15 May 2025		Q4 FY25Q1 FY27:The completion timeline for new factories, including the API plant, has been extended significantly. Management now states: 'Once we complete these factories, although it may take one or two years or two and a half years, we are sure of increasing our business manyfold.'
Call transcript, Q1 FY27 · 12 Aug 2026		Delayed

Source: Inve Guidance Tracker for Caplin Point Laboratories Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

2 of Caplin Point Laboratories Limited's 13 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 10 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹2,352.4 +3.45% · +₹78.5

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance +18.0% 1Y

₹1.5k₹2.0k₹2.5kOct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 6 Nov 2025Q3 FY26 — 5 Feb 2026Q4 FY26 — 14 May 2026Q1 FY27 — 12 Aug 2026

1Y: ₹1,993.1 on 24 Oct 2025 → ₹2,352.4. High ₹2,867.4 (24 Sept 2026), low ₹1,504.8 (30 Mar 2026).

Previous close
₹2,273.9
Market cap
₹17.3k Cr
52-week range
₹1,504.8 – ₹2,867.4
One year
+16.68%
Price to earnings (TTM to Jun 2026)
25.99×
Return on equity (TTM to Jun 2026)
22.15%

Overview

Symbol
NSE:CAPLIPOINT
Exchange
NSE
Currency
INR

What Caplin Point Laboratories Limited does

Based on the company's own presentations, annual report and earnings calls.

Caplin Point Laboratories is a Chennai-headquartered pharmaceutical company that manufactures and markets generic and branded-generic formulations, along with injectables and APIs, primarily for underserved markets in Latin America and Francophone Africa. It earns through a distribution-led, asset-light model - running in-house manufacturing facilities across Tamil Nadu, Puducherry and Andhra Pradesh while outsourcing part of production to Chinese partners - and increasingly through its own regulated-market front end, Caplin Steriles USA, which sells sterile injectables and ophthalmic products directly to US wholesalers and healthcare institutions. Its product basket spans thousands of registered products across dozens of therapeutic segments, and it has expanded from pure contract manufacturing into research-led drug development, including oncology, APIs and complex injectable dosage forms.

Segments

  • Emerging Markets (Latin America & Africa)
  • US & Other Regulated Markets
Countries with commercial presence
23
In-house manufacturing facilities
9
Dedicated R&D setups
5 (3 DSIR-approved)
Products registered globally
5,000+
Pharmaceutical formulations
650+
Therapeutic segments covered
36
Founded 1990Headquarters Chennai, Tamil Nadu, India Company website

How the price took the results

close before → close after

Q1 FY27
−6.0%
12 Aug
Q4 FY26
+9.9%
14 May
Q3 FY26
−0.3%
5 Feb
Q2 FY26
+0.5%
6 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Caplin Point Laboratories Limited

Free account: one company. Everything above stays public.

Write why you follow Caplin Point Laboratories Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Caplin Point Laboratories Limited

Guides on how to read this kind of business and the numbers that matter.